Advances in the diagnosis and treatment of diabetic peripheral neuropathy

Li Zhenhan, Chen Zhongpei, Yu Xiaoxia

PDF(544 KB)
PDF(544 KB)
Journal of Chongqing Medical University ›› 2025, Vol. 50 ›› Issue (05) : 574-578. DOI: 10.13406/j.cnki.cyxb.003772
Endocrine Regulation and Metabolic Diseases

Advances in the diagnosis and treatment of diabetic peripheral neuropathy

Author information +
History +

Abstract

As the population ages，the incidence of diabetes continues to climb. Diabetic peripheral neuropathy （DPN） occurs in about half of diabetic patients. DPN is characterized by the loss of peripheral nerve function from distal to proximal，with the main symptom of diffuse and persistent spontaneous intractable pain，which is one of the most common chronic complications of diabetes. DPN has a high mortality rate and poor prognosis，and the pathogenesis is not fully clear. The current focus of clinical treatment for DPN is to alleviate the clinical symptoms，as well as to control blood glucose and reduce the risk of adverse cardiovascular events. This study investigated the pathogenesis，diagnosis，and treatment of DPN and summarized the latest research progress to provide new ideas for clinical diagnosis and treatment of DPN.

Key words

diabetic peripheral neuropathy / risk factor / pathogenesis / diagnosis / treatment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Li Zhenhan , Chen Zhongpei , Yu Xiaoxia. Advances in the diagnosis and treatment of diabetic peripheral neuropathy. Journal of Chongqing Medical University. 2025, 50(05): 574-578 https://doi.org/10.13406/j.cnki.cyxb.003772

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Sun H， Saeedi P， Karuranga S，et al. IDF Diabetes Atlas：Global，regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract，2022，183：109119．
本文引用 [1]
2
Chang MC， Yang S. Diabetic peripheral neuropathy essentials：a narrative review[J]. Ann Palliat Med，2023，12（2）：390-398．
本文引用 [1]
3
Sloan G， Selvarajah D， Tesfaye S. Pathogenesis，diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy[J]. Nat Rev Endocrinol，2021，17（7）：400-420．
本文引用 [1]
4
Ling E， Lepow B， Zhou H，et al. The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes[J]. Clin Biomech，2020，73：157-161．
本文引用 [1]
5
Marshall A， Alam U， Themistocleous A，et al. Novel and emerging electrophysiological biomarkers of diabetic neuropathy and painful diabetic neuropathy[J]. Clin Ther，2021，43（9）：1441-1456．
本文引用 [1]
6
Selvarajah D， Kar D， Khunti K，et al. Diabetic peripheral neuropathy：advances in diagnosis and strategies for screening and early intervention[J]. Lancet Diabetes Endocrinol，2019，7（12）：938-948．
本文引用 [1]
7
Zakin E， Abrams R， Simpson MD. Diabetic Neuropathy[J]. Semin Neurol，2019，39（5）：560-569.
本文引用 [1]
8
Elafros MA， Andersen H， Bennett DL，et al. Towards prevention of diabetic peripheral neuropathy：clinical presentation，pathogenesis，and new treatments[J]. Lancet Neurol，2022，21（10）：922-936．
本文引用 [1]
9
Chen T， Xiao SJ， Chen ZD，et al. Risk factors for peripheral artery disease and diabetic peripheral neuropathy among patients with type 2 diabetes[J]. Diabetes Res Clin Pract，2024，207：111079．
本文引用 [2]
10
Cheng YF， Cao W， Zhang JZ，et al. Determinants of diabetic peripheral neuropathy and their clinical significance：a retrospective cohort study[J]. Front Endocrinol，2022，13：934020．
本文引用 [1]
11
UK Prospective Diabetes Study （UKPDS） Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes （UKPDS 33） [J]. Lancet，1998，352（9131）：837-853．
本文引用 [1]
12
Zhang XC， Yang X， Sun B，et al. Perspectives of glycemic variability in diabetic neuropathy：a comprehensive review[J]. Commun Biol，2021，4（1）：1366．
本文引用 [1]
13
Cardoso CL， Leite NC， Moram CM，et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes：The Rio de Janeiro Type 2 Diabetes Cohort Study[J]. Cardiovasc Diabetol，2018，17（1）：33．
本文引用 [1]
14
Callaghan BC， Little AA， Feldman EL，et al. Enhanced glucose control for preventing and treating diabetic neuropathy[J]. Cochrane Database Syst Rev，2012，2012（6）：CD007543．
本文引用 [1]
15
Handzlik MK， Gengatharan JM， Frizzi KE，et al. Insulin-regulated serine and lipid metabolism drive peripheral neuropathy[J]. Nature，2023，614（7946）：118-124．
本文引用 [1]
16
Huang YK， Zhang XY， Li B，et al. Association of BMI and waist circumference with diabetic microvascular complications：a prospective cohort study from the UK Biobank and Mendelian randomization analysis[J]. Diabetes Res Clin Pract，2023，205：110975．
本文引用 [1]
17
Sun LS， Zhang XR， Yang J，et al. Lower visceral fat is related to diabetic peripheral neuropathy[J]. Diabetes Metab Syndr Obes，2024，17：2967-2974．
18
Wang WM， Ji QH， Ran XW，et al. Prevalence and risk factors of diabetic peripheral neuropathy：a population-based cross-sectional study in China[J]. Diabetes Metab Res Rev，2023，39（8）：e3702．
本文引用 [2]
19
TODAY Study Group. Risk factors for diabetic peripheral neuropathy in adolescents and young adults with type 2 diabetes：results from the TODAY study[J]. Diabetes Care，2021：dc211074．
本文引用 [1]
20
Rümenapf G， Abilmona N， Morbach S，et al. Peripheral arterial disease and the diabetic foot syndrome：neuropathy makes the difference! A narrative review[J]. J Clin Med，2024，13（7）：2141．
本文引用 [1]
21
Ustinova M， Peculis R， Rescenko R，et al. Novel susceptibility loci identified in a genome-wide association study of type 2 diabetes complications in population of Latvia[J]. BMC Med Genomics，2021，14（1）：18．
本文引用 [1]
22
Vojtková J， Kolková Z， Motyková K，et al. An association between fibrinogen gene polymorphisms and diabetic peripheral neuropathy in young patients with type 1 diabetes[J]. Mol Biol Rep，2021，48（5）：4397-4404．
本文引用 [1]
23
Vujkovic M， Keaton JM， Lynch JA，et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis[J]. Nat Genet，2020，52（7）：680-691．
本文引用 [1]
24
Wang XX， Yang WH， Zhu YY，et al. Genomic DNA methylation in diabetic chronic complications in patients with type 2 diabetes mellitus[J]. Front Endocrinol，2022，13：896511．
本文引用 [1]
25
Jiao Y， Zhang YH， Wang CY，et al. MicroRNA-7a-5p ameliorates diabetic peripheral neuropathy by regulating VDAC1/JNK/c-JUN pathway[J]. Diabet Med，2023，40（1）：e14890．
本文引用 [1]
26
Jensen TS， Karlsson P， Gylfadottir SS，et al. Painful and non-painful diabetic neuropathy，diagnostic challenges and implications for future management[J]. Brain，2021，144（6）：1632-1645．
本文引用 [1]
27
Pop-Busui R， Boulton AJM， Feldman EL，et al. Diabetic neuropathy：a position statement by the American diabetes association[J]. Diabetes Care，2017，40（1）：136-154．
本文引用 [1]
28
Callaghan BC， Xia R， Reynolds E，et al. Better diagnostic accuracy of neuropathy in obesity：a new challenge for neurologists[J]. Clin Neurophysiol，2018，129（3）：654-662．
本文引用 [1]
29
Preventive Services Task Force US， Davidson KW， Barry MJ，et al. Screening for prediabetes and type 2 diabetes：us preventive services task force recommendation statement[J]. JAMA，2021，326（8）：736-743．
本文引用 [1]
30
Fernández-Torres R， Ruiz-Muñoz M， Pérez-Panero AJ，et al. Clinician assessment tools for patients with diabetic foot disease：a systematic review[J]. J Clin Med，2020，9（5）：1487．
31
Gewandter JS， Gibbons CH， Campagnolo M，et al. Clinician-rated measures for distal symmetrical axonal polyneuropathy：ACTTION systematic review[J]. Neurology，2019，93（8）：346-360．
32
Gylfadottir SS， Itani M， Krøigård T，et al. Diagnosis and prevalence of diabetic polyneuropathy：a cross-sectional study of Danish patients with type 2 diabetes[J]. Eur J Neurol，2020，27（12）：2575-2585．
本文引用 [1]
33
郭羽乔，李亦梅. 糖尿病周围神经病变治疗研究进展[J]. 临床医学进展，2023，13（6）：9013-9022.
Guo YQ， LI YM. Advances in the treatment of diabetic peripheral neuropathy[J]. Advances in Clinical Medicine，2023，13（6）：9013-9022.
本文引用 [1]
34
Xue TY， Zhang X， Xing YW，et al. Advances about immunoinflammatory pathogenesis and treatment in diabetic peripheral neuropathy[J]. Front Pharmacol，2021，12：748193．
本文引用 [1]
35
Ramasubbu K， Devi Rajeswari V. Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases：a perspective review[J]. Mol Cell Biochem，2023，478（6）：1307-1324．
本文引用 [1]
36
Kaur M， Misra S， Swarnkar P，et al. Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies[J]. Biochem Pharmacol，2023，215：115723．
本文引用 [1]
37
Ye L， Jiang Y， Zhang MM. Crosstalk between glucose metabolism，lactate production and immune response modulation[J]. Cytokine Growth Factor Rev，2022，68：81-92．
本文引用 [1]
38
Lin Y， Wei Y， Wei YH，et al. Dexmedetomidine alleviates oxidative stress and mitochondrial dysfunction in diabetic peripheral neuropathy via the microRNA-34a/SIRT2/S1PR1 axis[J]. Int Immunopharmacol，2023，117：109910．
本文引用 [1]
39
Baum P， Toyka KV， Blüher M，et al. Inflammatory mechanisms in the pathophysiology of diabetic peripheral neuropathy（DN）-new aspects[J]. Int J Mol Sci，2021，22（19）：10835．
本文引用 [1]
40
Zhu JX， Hu ZY， Luo YF，et al. Diabetic peripheral neuropathy：pathogenetic mechanisms and treatment[J]. Front Endocrinol，2024，14：1265372．
本文引用 [1]
41
Tesfaye S， Sloan G， Petrie J，et al. Comparison of amitriptyline supplemented with pregabalin，pregabalin supplemented with amitriptyline，and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain（OPTION-DM）：a multicentre，double-blind，randomised crossover trial[J]. Lancet，2022，400（10353）：680-690．
本文引用 [1]
42
Cernea S， Raz I. Management of diabetic neuropathy[J]. Metabolism，2021，123：154867．
43
Røikjer J， Mørch CD， Ejskjaer N. Diabetic peripheral neuropathy：diagnosis and treatment[J]. Curr Drug Saf，2021，16（1）：2-16．
本文引用 [1]
44
Jang HN， Oh TJ. Pharmacological and nonpharmacological treatments for painful diabetic peripheral neuropathy[J]. Diabetes Metab J，2023，47（6）：743-756．
本文引用 [1]
45
Yu XY， Zhang L， Yang XY，et al. Salvianolic acid A protects the peripheral nerve function in diabetic rats through regulation of the AMPK-PGC1α-Sirt3 axis[J]. Molecules，2012，17（9）：11216-11228．
本文引用 [1]
46
温祖辉，魏丹蕾，林春挺. 基于真实世界数据挖掘糖尿病周围神经病变中医病症组成规律[J]. 国际中医中药杂志，2022，44（9）：1044-1049．
Wen ZH， Wei DL， Lin CT. The constitution rule of TCM syndromes of diabetic peripheral neuropathy with real world data mining[J]. Int J Tradit Chin Med，2022，44（9）：1044-1049．
本文引用 [1]
47
Enders J， Elliott D， Wright DE. Emerging nonpharmacologic interventions to treat diabetic peripheral neuropathy[J]. Antioxid Redox Signal，2023，38（13/14/15）：989-1000．
本文引用 [1]

Comments

PDF(544 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉